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Abstract
Background: Chronic migraine is one of the most common diseases in the world and it is often associated with
medication overuse that can worsen the headache itself. Thus, it is important to adopt effective therapies to relieve
pain and improve patients’ quality of life. The PREEMT studies have already demonstrated the effectiveness of
OnabotulinumtoxinA in the treatment of chronic migraine. With this in mind, the aim of this real life observation
has been to assess the clinical improvements as well as the impact on the quality of life of patients being regularly
(every three months) administered this therapy.
Methods: Data from 66 chronic-migraineurs treated with OnabotulinumtoxinA after failing previous therapies were
collected. Only 57 of them were analysed since 9 discontinued the therapy due to administrative reasons. For every
patient enrolled, headache frequency, analgesic consumption, pain severity, headache-related disability, health-related
quality of life as well as anxiety and depression symptoms were collected through the Headache Index (HI), analgesic
consumption rate in one day (AC), VAS score, Headache Impact Test (HIT-6) and the Short Form (36) Health Survey
questionnaire Version 2 (SF-36®), Zung Self-Rating Anxiety Scale (ZUNG-A) and Zung Self-Rating Depression Scale
(ZUNG-D), respectively.
All the changes vs baseline (Tx vs T0) were expressed as mean ± SD and analysed with a one-way ANOVA plus
non-parametric Wilcoxon test, that was used for paired data for each subject.
Results: As the number of injection increased, those patients injected regularly observed a statistically significant
reduction in the headache frequency, pain intensity, headache disability score and an overall marked
improvement in patients’ quality of life. There was also a significant reduction in anxiety and depressive symptoms
as for the ZUNG-A and ZUNG-D scales scores. At any time point, those patients who stopped the therapy
worsened their overall conditions as confirmed by quality of life parameters.
Conclusions: This study outpoints that OnabotulinumtoxinA treatment is an effective treatment to reduce the
headache-related disability and improve patients’ quality of life when patients are treated regularly every three
months and consistently overtime. Therapy discontinuation leads to a general worsening of health-related quality
of life. Long term treatment over one year confirms a consistently positive and sustained trend of improvement
with a high safety profile.
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Background
Chronic migraine (CM) represents the most disabling
condition among headaches, in particular when it is as-
sociated with drug abuse.
CM, that is defined as the presence of headache for 15
or more days per month in patients with migraine his-
tory, dramatically decreases quality of life (QoL) and de-
termines an unquestionable morbidity in around 2 % of
the general population [1, 2]. Treatment of CM is not
worldwide scheduled and when analgesic overuse is
present withdrawal is compulsory. Even if many chronic
migraineurs need preventive treatments, there are well-
done trials only for topiramate [3, 4]. After one month
follow-up the majority of chronic-migraine patients re-
spond to withdrawal, whereas the consistency is short
and preventive drugs, alone or in combination, are
ineffective.
OnabotulinumtoxinA (OnabotA) was approved by the
FDA in 2010 for the preventive treatment of CM based
on the results collected in the Phase III Research Evalu-
ating Migraine Prophylaxis Therapy (PREEMPT) trial
[5]. Globally were enrolled 1354 individuals and were
evaluated the efficacy and safety of OnabotA as head-
ache prophylaxis in chronic-migraineurs, treated every
12 weeks for up to one year [6]. Since then a few studies
have recently demonstrated the effectiveness of Ona-
tobA in patients with MOH [7, 8], but data regarding
consistency of efficacy beyond one year of treatment are
limited. Furthermore, after one year lack of response oc-
curs in about one out of 9 patients and injections can be
delayed, but not stopped, to four months in around 40 %
of patients without relapsing in chronic headache [9].
Mechanism of action of OnabotA involved in reducing
migraine attacks in CM has not been completely eluci-
dated yet. However, it has been hypothesized that the re-
lease of neuropeptides induces vasodilation in meningeal
areas and neurogenic inflammation so that repeated epi-
sodes of activation of the trigemino-vascular system can
sensitize central pain pathways and lead to migraine
chronicization [10]. OnabotA inhibits the neurotrans-
mitters release and prevents neurogenic inflammation,
inhibiting both peripheral [11] and central sensitization
[12]. Moreover, it has been recently hypothesized that
the antinociceptive effect could depend also by centrally
mediated and axonal transport-dependent activity [13].
Patients with CM coming to our centre represent
more than 80 % of Day Hospital (DH) and in-ward pa-
tients. The patients considered in this analysis have been
treated only with OnabotA after almost one year of inef-
fective or slightly effective oral preventive treatments.
Medication overuse headache (MOH) may complicate
every type of headache and almost all the drugs
employed for acute headache treatment are taken by
MOH patients. These patients are difficult to treat due
to both their refractoriness to anti-migraine prophylactic
treatments and the frequent co-morbidities that often
need a multidisciplinary approach which might lead to
the prescription of a large amount of drugs.
In this observational study we included patients suffer-
ing from CM with MOH able to fill out diaries with no
lack of information, and who referred to our Headache
Clinic between May 2012 and May 2015. The treatment
with OnabotA (Botox®, provided by Allergan) is an im-
portant therapeutic option both for its efficacy and for
the safety profile [14]. The aim of our retrospective
evaluation was to assess the efficacy, consistency and
safety of OnabotA for repeated treatment cycles admin-
istered regularly every 3 months in a population with se-
vere CM and MOH.
Methods
In the Modena University Headache Centre we per-
formed a retrospective study in a sample of 66 patients
with a diagnosis of CM associated with medication over-
use according to the classification ICHD-III (beta). The
study was approved by the Ethical Provincial Committee
of Modena (protocol n. 729/E.C., file 334/15) and
conducted in compliance with the latest version of
the Declaration of Helsinki.
Aims of the study
The primary endpoint was to evaluate the reduction in
the headache index (HI, number of headache days/days
observed) and analgesic consumption (AC, number of
analgesic doses/days observed) in patients treated con-
sistently with OnabotA up to 7 cycles compared with
the baseline.
Secondary endpoints were the assessment of several
parameters mirroring the QoL by using self–reporting
scales (SF-36 and HIT-6 scales), anxiety and depression
(Zung A and D scales) and pain intensity (VAS scale) at
the beginning and at every injection session.
Outcome measures
Participants recorded headache characteristics using
consecutive monthly headache diaries that were completed
since 3 months before starting OnabotA and continued
throughout the entire treatment period.
The headache frequency was calculated as the number
of headache/migraine days over one month of observa-
tion and reported as Headache Index (HI). The analgesic
consumption was calculated as the number of analgesic
taken every month and reported as analgesic consump-
tion (AC).
The intensity of pain was scored by a visual analog
scale (VAS) with scores ranging from 0 = no pain to
10 =most severe pain, indicating the maximum pain
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score at every day and computing the mean value in
the observed month.
Headache-related disability and health-related QoL
were assessed at every injection session by using the six-
item Headache Impact Test (HIT-6) (HIT-6 Scoring Inter-
pretation Italy (Italian) Version 1.1 ©2001 QualityMetric,
Inc. and GlaxoSmithKline Group of Companies) and the
Short Form (36) Health Survey questionnaire Version 2
(SF-36®) (Istituto Ricerche Mario Negri, Milano, Italy).
Each HIT-6 question was scored as never (6 points), rarely
(8 points), sometimes (10 points), very often (11 points) or
always (13 points) with questions 4–6 relating to the past
4 weeks, for a total score of 36–78 (60 = severe impact,
56–59 = substantial impact, 50–55 = some impact,
and ≤49 = little to no impact).
The SF-36 contains eight scales relating to two summary
measures (physical component and mental component
summary scores). Each scale is scored between 0 = poor
QoL and 100 = good QoL [15].
Anxiety and depression symptoms were assessed at
every step of treatment with OnabotA according to the
Zung Self-Rating Anxiety Scale (ZUNG-A) as well as
Zung Self-Rating Depression Scale (ZUNG-D).
The Zung Self-Rating Depression Scale is a short self-
administered survey which describes the depressed sta-
tus of a patient. There are 20 items on the scale that deal
with affective, psychological and somatic symptoms as-
sociated with depression. For every item there is a list of
four answers that patient can chose and everyone of
them is associated with a specific mark. The higher the
overall mark, the worse the depression status. In a simi-
lar way, the Zung Self-Rating Anxiety Scale is a self-
administered survey whose score represents the anxiety
status in a patient. Also in this scale there are 20 items.
A patient is asked to provide an answer to each item
and every answer is associated with a mark. The total
score is calculated based on the sum of the single ones
and provides an overall idea of the anxiety status of the
patient [16].
Demographic data
We reviewed medical reports of 66 patients. However, in
this report we computed the data of only 57 patients
since they represent the ones who were injected regu-
larly every 3 months without interruption until up to
cycle 7 at least. In our real life experience, we have an
additional number of patients that have received up to
13 repeated cycles. However, they are not considered in
the current analysis and will be described in a future
data-set.
All data were collected by the clinical database in use
in our Centre.
The analysis was performed on patients referring to
the Headache Study Centre of Modena University,
between May 2012 and May 2015. All the patients ful-
filled criteria for CM and MOH as for the ICHD-III
(beta). Moreover, for this study we selected patients with
chronic (daily or near daily) headache suffering since
≥1 year and taking ≥1 analgesic/day. According to this,
these patients should be considered severe case of CM
and MOH. This criteria was chosen to consider a con-
sistent sample. Those patients who were not fulfilling
these parameters were not included.
The demographic data are summarized in Table 1.
These patients used a variety of antimigraine and pain
killer drugs. The data of primary and secondary drugs
overused at the start of Botox ® treatment are reported
in Table 2.
Nine patients discontinued the treatment as a conse-
quence of regional regulatory reasons due to a delay of
the registration procedure in our Regional Health Care
System. They stopped the treatment at different times.
Then, they were called and interviewed by phone from 4
to 6 months after the discontinuation to follow up on
their conditions. They were also asked if they wished
restarting the therapy with OnabotA.
Their results and considerations are reported apart for
discussion.
Treatment
All the patients were treated with OnabotA according to
the PREEMPT paradigm (155 U every three months into
31 injection sites) [5].
At day 0 (baseline), participants received OnabotA in-
jections and afterwords every three months according
with the PREEMPT protocol. Injections were adminis-
tered by an expert clinician as for the fixed-dose paradigm
across seven specific head-neck muscle areas.
Safety
All patients were counted only once for each adverse
event (AE) when multiple occurrences of the same AE
were reported, except that in the by-treatment-cycle ana-
lysis each new onset of an AE was counted in the cycle
in which it started. An on-going AE was not counted in
subsequent cycles unless it worsened.
Statistical analysis
All data were pooled and summarized with descriptive
statistics and appropriate tests were performed. Continu-
ous variables are reported as mean ± SD, categorical ones
Table 1 demographic characteristics
Sex Number Age BMI (kg/m2)
Male 11 49 ± 11 25.3 ± 2.8
Female 46 54.2 ± 13 20.4 ± 2
All (Mean ± SD) 57 50.5 ± 13.7 22.8 ± 2.3
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are reported as subjects-counts and percentages. The
mean change from baseline (and the 95 % confidence
interval for the mean change) for the number of head-
ache days at the final treatment cycle was computed.
The change of the outcome measures at each time point
versus the baseline value was compared using a one-way
ANOVA plus not parametric Wilcoxon test (Tx vs T0).
Changes in the explored endpoints among patients
who discontinued therapy were studied performing a
paired t-test.
Data in the Tables and Figures are expressed as
mean ± SD.
Results
The enrolled patients were older than those already de-
scribed in literature [17, 18]. This is probably due to the
restrictive parameters of choice that selected patients
with a long history of headache and with numerous at-
tempts to discontinue analgesic use. In the Table 1 are
reported also the number of treatment with Botox® every
three months as reported in the schedule of protocol.
The enrolled patients were 46 Female and 11 Male, aged
between 19 and 77 years (mean 50.5 ± 13.7), with a nor-
mal BMI (mean 22.8 ± 2.3).
In the Table 2, we report the types of overused drugs.
Many patients referred a constant and daily use of more
than one type of drug, in some cases of different classes.
Otherwise, there were patients using regularly two types
of triptans or two types of NSAIDs (Not Steroidal Anti
Inflammatory Drugs) simultaneously. We indicated as
primary drug overused the drug used daily as baseline to
prevent the incoming headache. Associated drugs were
the drugs used in the case of persistent pain or in the
case of recurrent headache and used always for more
than 15 days/month.
Only one patient took triptans and a pill containing
barbiturate (butalbital in association with phenazon and
caffeine, reported in the table as mixture). 35 out of 57
patients (61 %) reported the overuse of a single drug.
Overall, the most overused drugs were triptans, which
were primarily overused by 42 patients.
The complete results of the primary endpoint are re-
ported in the Table 3 as the number of days with head-
ache for month (HI) and mean number of analgesic
taken every day (AC). The results show a statistically sig-
nificant reduction of the Headache Index and Analgesic
Consumption at any injection session compared with
the basal status (P < 0.001). To better explain the impact
of the clinical response, in the Fig. 1 we have analyzed
the results also in terms of the percentage of reduction
of HI (in the upper graph) and AC (in the lower graph)
from the sixth-month injection (T6) to the eighteen-
month one (T18). They outline the high efficacy re-
sponse in terms of reduction of headache days and acute
drug intake achieved when patients are offered regularly
repeated treatments. Our observational results support
the importance of consistently treat patients to sustain
and improve their clinical outcomes. Already after 2
treatment cycles the HI was powerfully reduced of 22 %
vs the baseline value and it kept consistently reducing
overtime down to an additional 12 % at T18 (at the
cycle 7). Simultaneously, the AC greatly decreased with
an even higher trend vs the basal status from 26 % at
T6 to 67 % at T18.
The secondary endpoints results are reported in the
Table 4. We firstly evaluated the HIT-6 score, which was
significantly lower from the fifth injection (P < 0.05 for
T12, P < 0.01 for T15 and T18), while the VAS score
was significantly lower already after the second injec-
tion (P < 0.01). To better explain headache-related
disability as well as pain relief, we’ve reported the abso-
lute HIT-6 score reduction rate and the percentage of
VAS reduction in the Figs. 2 and 3, respectively. The
results not only have showed a very positive and con-
stant trend of reduction, but also highlight the valuable
impact on the QoL of our patients by a total HIT-6
score decrease of almost 12 point at T18 vs baseline
that is about 5 times higher the minimal important
difference. Our patients observed a very impactful
reduction in their disability further supported by a
important and sustained pain reduction of up to 47 %
at T18.
Table 2 Overused drugs
Overused drugs All
Primary Associated
Triptans 35 7 42
NSAIDs 9 10 19
Codeine containing drugs 6 8 14
Mixtures (Difmetrè®) 5 4 9
Tramadol 2 0 2
All 57 29 86
Table 3 Headache Index (HI) and Analgesic daily Consumption (AC)
T0 (n = 57) T3 (n = 57) T6 (n = 50) T9 (n = 36) T12 (n = 20) T15 (n = 13) T18 (n = 7)
Headache Index 0.98 ± 0.09 0.86 ± 0.24* 0.77 ± 0.3* 0.72 ± 0.34* 0.69 ± 0.29* 0.52 ± 0.29* 0.65 ± 0.36*
Analgesic consumption 1.79 ± 1.59 1.47 ± 1.67* 1.33 ± 1.90* 0.96 ± 0.97* 0.70 ± 0.43* 0.53 ± 0.30* 0.61 ± 0.42*
*P < 0.0001, one Way ANOVA +Wilcoxon test for paired data vs T0
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The SF-36 Mental and Physical scores were signifi-
cantly higher only after the sixth injection.
Data obtained with Zung-A and Zung-D scales were in-
consistent and probably this tests aren’t able to outline the
changes related to the headache modifications, when con-
sidering the modifications obtained in the QoL scores.
As described above, patients who discontinued be-
cause of regulatory reasons were considered separately
on the same items, and not pooled together due to the
differences in times of discontinuation and consistency
of treatment.
Overall, the patients who discontinued the treatment
suffered of a general worsening of their conditions
within 3 months. This worsening was different in terms
of outcomes according to the patient. However, a more
generalized marked negative impact in the QoL was con-
sistent for all of them as confirmed by the significative
decrease in both the SF-36 scales. In one case, we also
recorded that the AC newly increased up to 65 % when
comparing the values between before the interruption
and the first follow up visit to restart the OnabotA
treatment.
Adverse events
Overall, 33 of 57 patients (58 %) did not refer any AEs
during the treatment period. No serious AEs were re-
ported at any time. AEs considered definitely or prob-
ably related to the treatment occurred in 12 cases
(20 %), and were considered mild or (two cases) moder-
ate and were fully resolved after a short time. They in-
cluded cervical muscle pain, injection site bruising,
syncope following injection, tension type headache and
sensation of weight on neck. There were no significant
changes in any of vital signs from baseline and final time
for each patient. These results confirm the OnabotA tol-
erability profile already seen in real-life studies [14].
Discussion
CM represents migraine possible evolution from an epi-
sodic form, and MOH is the main and frequent compli-
cation or evolution of these patients. In 2012, Martelletti
reviewed therapeutic agents for re-prophylaxis after de-
toxification in patients with CM with and without medi-
cation overuse and reported that only topiramate and
local injection of OnabotA showed significant similar ef-
ficacy. Moreover, OnabotA was associated with a better
adverse events profile [19]; those results have also been
confirmed by Ahmed et al. in 2011 [7].
More recently, a review reported all the studies for
CM-MOH treatment and among articles investigating a
specific kind of preventive treatment, on a total of 17
studies, 5 of them reported the effect of OnabotA and 3
studies discussed the effect of topiramate, while a few
others reported the effects of other drugs, such as val-
proic acid, nabilone and pregabalin [20].
Fig. 1 Change in percentage of HI (upper) and AC (lower) from T6
to T18 compared to baseline. Our observational results confirmed
that already after 2 treatment cycles the HI was powerfully reduced
of 22 % vs the baseline value and it kept consistently reducing
overtime down to 34 % at T18 (at the cycle 7). This clinical
improvement was further raised up by a simultaneous marked trend
of reduction in AC vs the basal status that reached a 67 % at T18
Table 4 Secondary endpoints
T0 (n = 57) T3 (n = 57) T6 (n = 50) T9 (n = 36) T12 (n = 20) T15 (n = 13) T18 (n = 7)
HIT-6 score 63.94 ± 6.91 63.6 ± 6.89 62.14 ± 8.06 61.94 ± 8.13 58.55 ± 9.40* 55.7 ± 9.24** 52.28 ± 8.69**
VAS score 7.98 ± 1.26 6.98 ± 1.57** 6.01 ± 1.89** 5.19 ± 1.82** 5.14 ± 1.61** 4.69 ± 1.75** 4.25 ± 1.48**
SF-36 Mental 48.30 ± 21.68 50.41 ± 22.50 51.71 ± 22.35 52.82 ± 23.44 59.41 ± 21.16 67.8 ± 16.8** 73.90 ± 20.26*
SF-36Physical 46.35 ± 18.90 46.85 ± 20.21 49.17 ± 19.90 48.94 ± 19.80 52.58 ± 24.69 62.11 ± 23.5* 70.18 ± 23.22*
ZUNG-A 41.27 ± 10.26 20.69 ± 9.82 40.76 ± 10.39 39.43 ± 9.74 37.48 ± 9.43 35.08 ± 7.11* 34 ± 6.11
ZUNG-D 42.95 ± 11.25 42.80 ± 11.31 43.4 ± 12.08 41.32 ± 10.03 38.23 ± 10.39 35.69 ± 7.82 37.14 ± 7.65
*P < 0.05; **P < =0.01 ANOVA followed by Wilcoxon test for paired data versus T0
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In our experience, the primary endpoints rapidly
reached a statistical significance compared with baseline
already after three months, confirming the results re-
cently outpointed by Negro et al. [14]. An even more
clinically and marked relevance was obtained at the T6
session both for HI and AC. In particular, Figure 1
shows that within 3 months, between the third and the
fifth injection there is a reduction of the HI of about
9 %. Moreover, between the fifth and the seventh injec-
tion there is a reduction of 3 % of the HI. Globally, be-
tween the third and the seventh injection the headache
days within a month decreased of about 13 %. It is pos-
sible hypothesize that the high reduction in HI and AC
in the first period reflects both the pharmacological and
the placebo effect together that we can collect at the
beginning of the treatment..In fact, also in the PRE-
EMPT extension the gap between treated and placebo
were significant in the double blind period, whereas after
that both the curves were parallel [6].
In terms of secondary endpoints, the HIT-6 was sig-
nificantly reduced only after 12 months and the score
ameliorated in the subsequent sessions. Fig. 2 shows that
there is a global reduction of 10 % in the HIT-6 Score
between the third and the seventh injection. This result
has also been recently confirmed by Khalil et al. [21].
Anxiety and depression scales showed a small im-
provement and only in a session we registered a signifi-
cant reduction of anxiety scale. This result disagrees
with Boudreau who reported improvements of the same
parameters we used, out of depression. In fact, in a six
months study they reported that Botox® was effective
over headache frequency and analgesic consumption,
headache impact on QoL, related disability was effective
in reducing also depression and anxiety symptoms [22].
The discrepancies are probably due to the different tests
used in measuring anxiety and depression symptoms, as
well as the characteristics of sample. In fact, in our sam-
ple the scores of the specific tests for QoL at baseline
were lower than in other series confirming the severity
of our patients as compared with other series reported
in literature [23].
The evaluation of QoL with SF-36 questionnaire
showed a significant improvement after one year of
treatment. Both mental and physical scores increased
during all the observation period confirming a very
positive trend. Furthermore, these scores worsened
rapidly and with statistical significance after therapy
discontinuation.
In our patients no serious AEs were recorded at any
time. AEs treatment-related occurred in 20 % of cases,
all of mild or moderate (two cases) intensity and were
spontaneously and rapidly resolved within some hours
and without specific treatments. All these AEs were of
type 1 and no drop-out were related to these events.
Conclusions
There are two main items to be discussed in this study:
 The consistency of efficacy and sustained benefit of
the OnabotA treatment over the time
 the effect on analgesic drug use over the time in
MOH patients
The consistency of Botox® in the long term treatment
was not resolved in the PREEMPT studies, such as the
questions about the overall duration of treatment, the
length of withdrawal of treatment at scheduled times,
and if these interruptions have to be done are still in
debate.
Fig. 2 Change vs baseline in the HIT-6 score questionnaire from T6
to T18. Absolute HIT-6 Score reduction rate. The results show a
positive and constant trend of reduction, and highlight the marked
improvement in the QoL as demonstrated by a total HIT-6 score
decrease of almost 12 points at T18 vs baseline (about 5 times
higher the minimal important difference)
Fig. 3 Change in percentage of VAS score vs baseline from T6 to
T18. A positive and sustained trend of pain intensity reduction was
observed overtime in our patients vs baseline
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This retrospective survey on a series of severe patients
we followed for many years and treated with fixed doses
suggests a number of points we can discuss.
The improvement of the primary endpoints was ob-
served rapidly and consistently during all the observed
treatment period. Those patients who discontinued the
treatment because of legal reasons, worsened after some
weeks and renewed improvement after 3 or 6 months
after being administered a new OnabotA treatment.
Patients who continued without any interruption
showed an increasing and progressive improvement
without reduction of efficacy both in HI and in AC. The
score related to the QoL improved only after one year of
treatment thus suggesting that the real improvement
and the exit from daily headache needs many months to
be consolidated.
The second point we want to discuss concerns the role
of the analgesic daily use (so called overuse or misuse or
abuse). The patients we examined were all daily con-
sumers of 1 to 5 analgesic drugs to reduce or try to pre-
vent (unsuccessfully) their headache attacks.
There is a large debate on the role of analgesics and
triptans in chronicization or sensitization of chronic mi-
graine and headaches, but at the moment we would like
to discuss only if the drug discontinuation was essential
to obtain clinical improving. [24].
The results in literature indicate that OnabotA, with-
out early discontinuation of the overused medication,
was effective and well tolerated as headache prophylaxis
in CM with MOH patients, even if these data were ob-
tained only after post-hoc analysis [7, 17, 25].
Considering current available evidence, Chiang sug-
gests discontinuation of the overused medication with
the addition of preventive medication and hopes “Stud-
ies on preventive medications plus early discontinuation
vs preventive treatment alone vs early discontinuation
alone are needed” [20]. Our data shows that the discon-
tinuation in drugs overuse, related to the decrease in AC
score is linked with the reduction of VAS score and the
headache-related disability according to the HIT-6 score
change.
Our data can confirm this point based on our previous
experiences according on the beneficial effect due to an
early medication discontinuation even on the psycho-
logical structure and compliance of patients in the
scheduled program [26, 27].
In conclusion, we can confirm that in accordance
with literature data patients with chronic migraine CM
and MOH are responsive to the use of OnabotA with
an early discontinuation of medication overused. This
treatment is also consistent and safe over long time.
Furthermore, patients who discontinue the treatment
are exposed at a high risk of a general health quality
regression.
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